Navigation Links
Pharmasset Receives $10 Million of Working Capital
Date:3/28/2008

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Pharmasset does not receive all or any portion of the funds from the working capital loan agreement with Horizon, the risk that we will default on any of the loans causing all of the loans to be immediately due and payable and allowing Horizon to terminate the loan agreement, the risk that adverse events could cause the cessation of the Phase 3 studies and/or our development of clevudine, the risk that the registration clinical trials of clevudine will not be successful or will not provide meaningful data, the risk that we will fail to release final safety and efficacy data from a Phase 1 combination study of R7128 with Pegasys plus Copegus or that such final data will not corroborate our preliminary results, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successfully developed or will not provide clinically meaningful data and the risk that any one or more of our product candidates will not be commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Appoints Herbert J. Conrad as a Director
2. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
3. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
4. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
5. Pharmasset Reports Fiscal Year End 2007 Financial Results
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. Pharmasset to Present at Three Investor Conferences in November 2007
8. Pharmasset Accesses up to $30 Million of Working Capital
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
10. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources Group ... medical directors in the United States ... biosimilar market penetration will be the level of ... and the expected lower cost to patients. Payers ... that meet their pricing expectations in order to ...
(Date:7/30/2014)... July 30, 2014  The Chicago Bears are excited ... of Dermatology (Academy) in an effort to raise awareness ... will host free SPOT me™ skin cancer screenings at ... Soldier Field. SPOT me™ is an educational campaign ... dangers and risks of skin cancer, and encourages people ...
(Date:7/30/2014)... While administrative claims and other ... for a relatively long period of time, there ... use of these ‘big data’ for comparisons of ... today’s powerful computer technology with the plethora of ... holds significant promise for identifying optimal interventions for ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2
... The National Science Foundation,(NSF) has awarded Loma ... of $593,978 to lead a consortium in developing ... universities. Barry L. Taylor, Ph.D., Professor of Microbiology,and ... Affairs,will lead the project with Rohit Shukla, CEO ...
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) announced ... studies of PX-12 and preclinical studies of,PX-866 will ... American Association,for Cancer Research (AACR) in San Diego ... a Phase 1 clinical trial of PX-478,in patients ...
... Biopure,Corporation (Nasdaq: BPUR ) announced today that ... its independent auditor., The audit committee of ... review of audit firms that had expertise with ... in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. ...
Cached Biology Technology:Loma Linda University Partners With Larta Institute for Technology Marketing Program 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
(Date:7/30/2014)... ranges and a changing climate threaten some of ... and so conservationists establish seed collections to save ... hopes of preserving some genetic diversity., For decades, ... models that offer a one-size-fits-all approach for how ... 50 seed samples regardless of species, pollination mode, ...
(Date:7/30/2014)... searching through a massive collection of 20-million-year-old amber found ... and the effort is yielding fresh insights into ancient ... the collection is fully curated, a task that will ... Dominican amber collection in the world, the researchers report. ... is that of a pygmy locust, a tiny grasshopper ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Saving seeds the right way can save the world's plants 2Decades-old amber collection offers new views of a lost world 2
... U.S. Department of,Homeland Security (DHS) announced today ... international visitors arriving at Boston,Logan International Airport ... department,s,upgrade from two- to 10-fingerprint collection to ... accurately and efficiently,establishing and verifying visitors, identities., ...
... About the Ocean Sciences Meeting News Media Registration ... 4 February 2008 Abstracts and Schedule Available Online Who,s ... This years meeting will offer a wealth of new ... it is found, from mountain peaks to deep ocean ...
... bring a combination of individual scientific skills, expertise ... these offer the opportunity to build a highly ... address the urgent need for bringing new antibiotic ... antibiotics and other antimicrobial agents have saved millions ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at Boston Logan International Airport 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4Unique fungal collection could hold key to future antibiotics 2Unique fungal collection could hold key to future antibiotics 3
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Immunochemistry 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: